FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.10  |  FHIR Version n/a  User: [n/a]

15440511000001107: Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 01-Oct 2009. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
54766001000001117 Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
54766101000001116 Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Is a Generic Stalevo 125mg/31.25mg/200mg tablets 100 tablet true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Has excipient Polysorbate false Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet VMP prescribing status (attribute) Never valid to prescribe as a VMP false Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Legal category Prescription only medicine - legal category (qualifier value) true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Discontinued indicator Never discontinued true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Has AMP Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Has specific active ingredient Carbidopa true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Has specific active ingredient Entacapone true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Has specific active ingredient Levodopa true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Has dispensed dose form Tablet true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet Is a Actual medicinal product pack true Inferred relationship Existential restriction modifier
Stalevo 125mg/31.25mg/200mg tablets (Orion Pharma (UK) Ltd) 100 tablet VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group

This concept is not in any reference sets

Back to Start